Taken together, in-depth proteomic profiling together with CRISPR‒Cas9 screens in PDX identified ADAM10 as an in vivo vulnerability in leukemia cells and LSC and indicate that ADAM10 may represent a therapeutic target to treat acute leukemias. This evidence concerns the gene ADAM10 and acute leukemia.